Clinical Trial Update: A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS [Phase 2]

View source ↗

Summary

Phase 2 study evaluating multiple-dose, dose-escalation of AEB1102 in patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AEB1102

Snippet

Sponsor: Aeglea Biotherapeutics | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED